Key Dates

Related Announcements

• July 12, 2023 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed). See NOFO PA-23-232
• July 12, 2023 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required). See NOFO PA-23-233
• July 12, 2023 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required). See NOFO PA-23-231
• July 12, 2023 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed). See NOFO PA-23-230
• May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See NOFO PA-20-185
• May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required). See NOFO PA-20-196
• May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed). See NOFO PA-20-195
• May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required). See NOFO PA-20-194
• December 11, 2020 - NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required). See NOFO PAR-21-063
• December 20, 2020 - NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional). See NOFO PAR-21-107

Issued by

National Institute on Deafness and Other Communication Disorders (NIDCD)

Purpose

Post-acute sequelae of SARS-CoV-2 (PASC), also referred to as long COVID, is defined as signs, symptoms, and conditions that continue or develop after initial COVID-19 infection. Such signs, symptoms, and conditions linger or develop 4 or more weeks following the acute infection, and can last weeks, months, and even years. Furthermore, PASC-related symptoms are wide ranging, and can have cardiopulmonary, gastrointestinal, dermatologic, endocrine, psychiatric and/or neurological manifestations, including sensory dysfunction and cognitive-communication difficulties. Further research is critical to understand the symptomatology, pathogenesis, and underlying mechanisms of PASC. NIDCD invites applications for research on PASC in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

Areas of research encouraged through this NOSI must focus on the manifestations of PASC in relation to NIDCD’s scientific mission areas and include, but are not limited to:  

• Studies on the prevalence, onset, and resolution of acquired deficits among patients with PASC across the lifespan
• Characterization of long-term post-acute sequelae following SARS-CoV-2 infection
• Research on the genetic predispositions, environment factors, and health conditions contributing to PASC susceptibility and severity
• Studies on the underlying molecular mechanisms and pathobiology leading to dysfunction associated with PASC
• Research on potential toxicity or tissue damage to the auditory, vestibular, or chemosensory systems due to infection and therapeutics related to PASC
• Development and validation of animal models and in vitro systems replicating aspects of PASC
• Studies of the multiple mechanisms proposed to play a role in PASC (ongoing exacerbated inflammatory response, persistent viral reservoirs, SARS-CoV2-evoked autoimmunity and others)
• Multidisciplinary collaborative research to study PASC and to develop approaches (such as technical innovations related to telemedicine) for providing effective and equitable health services

Applications Not Responsive to this NOSI: 

Applications proposing the following will be considered non-responsive to this NOSI:

• Research on PASC unrelated to NIDCD’s mission areas of hearing, balance, taste, smell, voice, speech, and language.
• Research focused solely on the acute phase of SARS-CoV-2 infection.

Application and Submission Information

This notice applies to due dates on or after January 30, 2024 and subsequent receipt dates through January 30, 2027.

Submit applications for this initiative using one of the following funding opportunities or any reissues of these opportunities through the expiration date of this notice.

PAR-21-063 - NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required)

PAR-21-107 - NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

PA-23-232- PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

PA-23-233 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

PA-23-231- PHS 2019-02 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

PA-23-230 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

All instructions in the SF424 (R&R) Application Guide and the notice of funding opportunity used for submission must be followed, with the following additions:

• For funding consideration, applicants must include “NOT-DC-24-001” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed notice of funding opportunity with the following additions/substitutions:

Scientific/Research Contact(s)

Susan Sullivan, Ph.D.

National Institute on Deafness and Other Communication Disorders (NIDCD

Phone: 301-451-3841

[email protected]

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Samantha Tempchin
National Institute on Deafness and Other Communication Disorders (NIDCD)
Telephone: 301-435-1404
Email: [email protected]